微RNA-502在胃癌中的表达及其临床意义

Expression of microRNA-502 in gastric cancer tissues and its clinical significance

目的分析胃癌患者微RNA-502(miRNA-502)的表达及其与重要临床病理特征的关系。方法采用实时定量PCR检测28例胃癌组织及其配对正常癌旁组织中miRNA-502的表达量。比较不同年龄、性别、癌组织人表皮生长因子受体(HER)-2蛋白质表达、血清糖类抗原(CA)19-9、血清癌胚抗原(CEA)、临床分期的患者癌组织中miRNA-502表达量的差异。分析miRNA-502表达与胃癌患者不同临床病理特征的关系。结果胃癌组织中miRNA-502的相对表达量显著低于癌旁组织(P<0.01)。胃癌T分期为T_(1～2)期、无淋巴结转移的患者miRNA-502相对表达量分别显著高于T_(3～4)期(P<0.001)和有淋巴结转移(P=0.03)的患者,而不同年龄、性别、癌组织HER-2蛋白质表达、血清CA19-9和CEA水平的患者癌组织miRNA-502相对表达量的差异均无统计学意义(P值均>0.05)。COX回归分析结果显示,miRNA-502的相对表达量与胃癌T分期显著相关[风险比(HR)=1.62,95%CI为1.34～1.96,P=0.028],而与年龄、性别、癌组织HER-2蛋白质表达、淋巴结转移状态、血清CEA和CA19-9水平均不相关(P值均>0.05)。结论胃癌患者肿瘤组织中miRNA-502表达水平明显下降,且与胃癌的局部浸润密切相关,miRNA-502可能是胃癌的潜在肿瘤标志物。

Objective To explore the expression of microRNA-502(miRNA-502) and its correlation with clinicopathological features of gastric cancer.Methods A total of 28 gastric cancer patients were enrolled in the study.Quantitative real time polymerase chain reaction(qRT-PCR) was used to detect the expression of miRNA-502 in cancer tissues and its paired-adjacent normal tissues.The expression of miRNA-502 was compared between patients with different ages,genders,human epidermal growth factor receptor(HER)-2 statuses,carbohydrateantigen(CA)19-9 level,carcinoembryonic antigen(CEA)level,and T stages.The correlation between miRNA-502 and clinicopathological features of gastric cancer was analyzed.Results The expression of miRNA-502 in the gastric cancer tissues was significantly lower than that in the adjacent normal tissues(P<0.01).The expressions of miRNA-502 in patients with T1-2 stage and non-lymph node metastasis were lower than those in patients with T3-4 stage(P<0.001)and lymph node metastasis(P=0.03),respectively.Multivariate analysis showed that the expression of miRNA-502 was correlated with T staging(hazard ratio[HR]=1.62,95%CI=1.34-1.96,P=0.028),but not with age,sex,HER-2status,lymph node metastasis,CEA or CA19-9(all P>0.05).Conclusion Thelevel of miRNA-502 is decreased in gastric cancer patients and closely related to the local progression.miRNA-502 may be a candidate tumor marker during the progression of gastric cancer.